Kamada (NASDAQ:KMDA) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Insider & Institutional Ownership
13.0% of Kamada shares are held by institutional investors. Comparatively, 63.7% of OptiNose shares are held by institutional investors. 44.3% of OptiNose shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Kamada and OptiNose’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Kamada and OptiNose, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kamada presently has a consensus price target of $9.00, suggesting a potential upside of 53.32%. OptiNose has a consensus price target of $27.25, suggesting a potential upside of 240.63%. Given OptiNose’s higher probable upside, analysts plainly believe OptiNose is more favorable than Kamada.
Valuation and Earnings
This table compares Kamada and OptiNose’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kamada||$114.47 million||2.06||$22.30 million||$0.55||10.67|
|OptiNose||$7.07 million||46.69||-$106.66 million||($2.68)||-2.99|
Kamada has higher revenue and earnings than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Kamada has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, OptiNose has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.
Kamada beats OptiNose on 8 of the 13 factors compared between the two stocks.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, Kamada Ltd. provides Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. Its products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent, which are in Phase II stage; and D1-AAT (IV) for type-1 diabetes, Inhaled AAT for AAT deficiency, and AAT (liquid) for lung preservation and recombinant AAT, which are in early stage development. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion S.p.A. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel.
OptiNose Company Profile
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. It has a license agreement with Inexia Limited to manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.